Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
| Autor: | Steven G. Potkin, Richard L. O'Sullivan, George M. Simpson, Peter J. Weiden |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Olanzapine medicine.medical_specialty Adolescent medicine.drug_class medicine.medical_treatment Atypical antipsychotic Schizoaffective disorder Severity of Illness Index Piperazines Benzodiazepines Internal medicine Ambulatory Care medicine Humans Ziprasidone Psychiatry Antipsychotic Psychiatric Status Rating Scales Cross-Over Studies Risperidone Positive and Negative Syndrome Scale Pirenzepine Middle Aged medicine.disease Thiazoles Psychiatry and Mental health Treatment Outcome Tolerability Schizophrenia Female Schizophrenic Psychology Psychology Antipsychotic Agents medicine.drug |
| Zdroj: | The Journal of Clinical Psychiatry. 64:580-588 |
| ISSN: | 0160-6689 |
| DOI: | 10.4088/jcp.v64n0514 |
| Popis: | Background: Many outpatients with schizophrenia experience persistent symptoms or side effects on their current antipsychotic regimen. Few studies have prospectively examined the effects of the prior medication or switching method on the safety and efficacy of a newly available antipsychotic. Efficacy and tolerability of ziprasidone were evaluated in patients with DSM-IV schizophrenia or schizoaffective disorder who were switched from conventional or atypical antipsychotics in three 6-week, multicenter, randomized, open-label, parallel-group trials. Method: Stable outpatients with persistent symptoms or troublesome side effects on (1) conventional antipsychotic (N = 108), (2) olanzapine (N = 104), or (3) risperidone (N = 58) therapy were switched to an open-label, 6-week, flexible-dose trial of ziprasidone (40-160 mg/day). Patients were randomly assigned at baseline to 1 of 3 switching schedules during the first week of ziprasidone therapy. Baseline and outcome assessments included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impressions of Severity (CGI-S) ratings. Results: All 3 switching strategies were well tolerated for all 3 patient groups. After 6 weeks on ziprasidone therapy, significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|